Enanta Pharmaceuticals (ENTA) Stock Forecast & Price Target

Compare

190 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ENTA Analyst Ratings

Strong Buy

4 Buy

1 Hold

0 Sell

Based on 5 analysts giving stock ratings to

Enanta

Pharmaceuticals

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ENTA Stock 12 Month Forecast

Average Price Target

$15.60

▲(1.36% Upside)

Based on 5 Wall Street analysts offering 12 month price targets for Enanta Pharmaceuticals in the last 3 months. The average price target is $15.60 with a high forecast of $20.00 and a low forecast of $9.00. The average price target represents a 1.36% change from the last price of $15.39.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","21":"$21","8.25":"$8.25","12.5":"$12.5","16.75":"$16.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$20.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15.6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$15.60</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$9.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,8.25,12.5,16.75,21],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.14,14.590769230769231,15.041538461538462,15.492307692307692,15.943076923076923,16.393846153846155,16.844615384615384,17.295384615384616,17.746153846153845,18.196923076923078,18.647692307692306,19.09846153846154,19.549230769230768,{"y":20,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.14,14.252307692307692,14.364615384615385,14.476923076923077,14.58923076923077,14.701538461538462,14.813846153846153,14.926153846153847,15.038461538461538,15.150769230769232,15.263076923076923,15.375384615384615,15.487692307692308,{"y":15.6,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.14,13.744615384615384,13.34923076923077,12.953846153846154,12.55846153846154,12.163076923076924,11.767692307692307,11.372307692307693,10.976923076923077,10.581538461538461,10.186153846153847,9.79076923076923,9.395384615384614,{"y":9,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":8.57,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.75,"date":1735689600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":5.11,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.78,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.32,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.05,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.29,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.7,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.11,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.61,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.96,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.14,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$20.00

Average Price Target$15.60

Lowest Price Target$9.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Brandon Folkes

H.C. Wainwright

$20

Buy

29.95%

Upside

Reiterated

11/18/25

Enanta Pharmaceuticals: Promising Pipeline and Strong Financial Position Justify Buy RatingValuation and Risks. We base our valuation on our discounted cash flow (DCF), where we use a weighted average cost of capital (WACC) of 15.1%, and an exit multiple of 10.0x on our 2034 estimates. We assign a 50% probability of success to Zelicapavir in RSV and take a conservative approach in ascribing value to the rest of the company’s pipeline at this stage. We assume a late 2029 or early 2030 launch for Zelicapavir in RSV. Risks include: 1) Clinical development risk, 2) Regulatory risks, 3) Commercial risk, and 4) Intellectual property risk.

Anupam Rama

J.P. Morgan

$17

Buy

10.46%

Upside

Initiated

11/14/25

Buy Rating for Enanta Pharmaceuticals Driven by Promising RSV Drug Pipeline and Market Potential

Akash Tewari

Jefferies

$14→$20

Buy

29.95%

Upside

Upgraded

10/01/25

Enanta upgraded to Buy from Hold at JefferiesEnanta upgraded to Buy from Hold at Jefferies

Roanna Ruiz

Leerink Partners

$7→$9

Hold

-41.52%

Downside

Reiterated

10/01/25

Leerink Partners Reaffirms Their Hold Rating on Enanta Pharmaceuticals (ENTA)Leerink Partners analyst Roanna Ruiz raised the price target on Enanta Pharmaceuticals (NASDAQ: ENTA) to $9.00 (from $7.00) while maintaining a Market Perform rating.

Jonathan Miller

Evercore ISI

$12

Buy

-22.03%

Downside

Reiterated

09/30/25

Evercore ISI Keeps Their Buy Rating on Enanta Pharmaceuticals (ENTA)

Unknown Analyst

Westpark Capital

Not Ranked

Westpark Capital

$24

Buy

55.95%

Upside

Initiated

09/02/25

Enanta initiated with a Buy at WestPark CapitalEnanta initiated with a Buy at WestPark Capital

Roy Buchanan

Citizens JMP

$24→$25

Buy

62.44%

Upside

Reiterated

08/12/25

Enanta price target raised to $25 from $24 at Citizens JMPEnanta price target raised to $25 from $24 at Citizens JMP

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Brandon Folkes

H.C. Wainwright

$20

Buy

29.95%

Upside

Reiterated

11/18/25

Anupam Rama

J.P. Morgan

$17

Buy

10.46%

Upside

Initiated

11/14/25

Buy Rating for Enanta Pharmaceuticals Driven by Promising RSV Drug Pipeline and Market Potential

Akash Tewari

Jefferies

$14→$20

Buy

29.95%

Upside

Upgraded

10/01/25

Enanta upgraded to Buy from Hold at JefferiesEnanta upgraded to Buy from Hold at Jefferies

Roanna Ruiz

Leerink Partners

$7→$9

Hold

-41.52%

Downside

Reiterated

10/01/25

Jonathan Miller

Evercore ISI

$12

Buy

-22.03%

Downside

Reiterated

09/30/25

Evercore ISI Keeps Their Buy Rating on Enanta Pharmaceuticals (ENTA)

Unknown Analyst

Westpark Capital

Not Ranked

Westpark Capital

$24

Buy

55.95%

Upside

Initiated

09/02/25

Enanta initiated with a Buy at WestPark CapitalEnanta initiated with a Buy at WestPark Capital

Roy Buchanan

Citizens JMP

$24→$25

Buy

62.44%

Upside

Reiterated

08/12/25

Enanta price target raised to $25 from $24 at Citizens JMPEnanta price target raised to $25 from $24 at Citizens JMP

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Enanta Pharmaceuticals

1 Month

xxx

Success Rate

18/37 ratings generated profit

Average Return

-0.93%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 48.65% of your transactions generating a profit, with an average return of -0.93% per trade.

3 Months

xxx

Success Rate

13/37 ratings generated profit

Average Return

-4.74%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 35.14% of your transactions generating a profit, with an average return of -4.74% per trade.

1 Year

Roy BuchananCitizens JMP

Success Rate

11/37 ratings generated profit

Average Return

-11.14%

reiterated a buy rating 4 months ago

Copying Roy Buchanan's trades and holding each position for 1 Year would result in 29.73% of your transactions generating a profit, with an average return of -11.14% per trade.

2 Years

xxx

Success Rate

13/37 ratings generated profit

Average Return

-20.58%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 35.14% of your transactions generating a profit, with an average return of -20.58% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ENTA Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ENTA has received 3 Buy Ratings, 5 Hold Ratings, and 0 Sell Ratings. ENTA average Analyst price target in the past 3 months is 15.60.

Each month's total comprises the sum of three months' worth of ratings.

ENTA Financial Forecast

ENTA Earnings Forecast

Next quarter’s earnings estimate for ENTA is -$0.81 with a range of -$1.23 to -$0.53. The previous quarter’s EPS was -$0.87. ENTA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year ENTA has Performed in-line its overall industry.

ENTA Sales Forecast

Next quarter’s sales forecast for ENTA is $16.05M with a range of $14.65M to $16.56M. The previous quarter’s sales results were $15.13M. ENTA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year ENTA has Performed in-line its overall industry.

ENTA Stock Forecast FAQ

What is ENTA’s average 12-month price target, according to analysts?

Based on analyst ratings, Enanta Pharmaceuticals’s 12-month average price target is 15.60.

What is ENTA’s upside potential, based on the analysts’ average price target?

Enanta Pharmaceuticals has 1.36% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is ENTA a Buy, Sell or Hold?

Enanta Pharmaceuticals has a consensus rating of Strong Buy which is based on 4 buy ratings, 1 hold ratings and 0 sell ratings.

What is Enanta Pharmaceuticals’s price target?

The average price target for Enanta Pharmaceuticals is 15.60. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $20.00 ,the lowest forecast is $9.00. The average price target represents 1.36% Increase from the current price of $15.39.

What do analysts say about Enanta Pharmaceuticals?

Enanta Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.

How can I buy shares of ENTA?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Enanta Pharmaceuticals (ENTA) Stock Forecast & Price Target

ENTA Analyst Ratings

ENTA Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Enanta Pharmaceuticals

ENTA Analyst Recommendation Trends

ENTA Financial Forecast

ENTA Earnings Forecast

ENTA Sales Forecast

ENTA Stock Forecast FAQ

Detailed List of Analyst Forecasts